Carboplatin
Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.
| ID | DRUG-CARBOPLATIN |
|---|---|
| Тип | Препарат |
| Синоніми | ParaplatinКарбоплатин |
| Статус | переглянуто 2026-04-26 | очікує клінічного підпису |
| Хвороби | DIS-ANAL-SCC DIS-BREAST DIS-BURKITT DIS-CERVICAL DIS-EATL DIS-ENDOMETRIAL DIS-ESOPHAGEAL DIS-GRANULOSA-CELL DIS-HNSCC DIS-HSTCL DIS-NSCLC DIS-OVARIAN DIS-PMBCL DIS-SALIVARY DIS-SCLC DIS-THYROID-ANAPLASTIC DIS-UROTHELIAL |
| Джерела | SRC-NCCN-BCELL-2025 SRC-NCCN-ESOPHAGEAL-2025 |
Дані про препарат
| Клас | Platinum alkylating agent (second-generation) |
|---|---|
| Механізм дії | Cisplatin analog with a cyclobutane-dicarboxylate leaving group that hydrolyzes more slowly than cisplatin's chloride ligands → slower formation of activated aquated species, lower reactivity with plasma proteins, and lower nephrotoxicity / ototoxicity / neurotoxicity. The same DNA platinum-adduct biology drives cytotoxicity. Dose individualized by Calvert formula because clearance is dominated by glomerular filtration. Myelosuppression — particularly thrombocytopenia — is the dose-limiting toxicity. |
| Типове дозування | Calvert formula: dose (mg) = AUC × (GFR + 25). GFR cap at 125 mL/min recommended (FDA 2010) when measured by Cockcroft-Gault to avoid overdose in patients with overestimated GFR. Ovarian 1L (carbo/paclitaxel): AUC 5-6 IV q21d × 6 cycles. NSCLC (carbo/paclitaxel): AUC 6 IV q21d × 4-6 cycles. CROSS (esophageal CRT): AUC 2 IV weekly × 5 with paclitaxel 50 mg/m². ICE (lymphoma salvage): AUC 5 (max 800 mg) IV day 2. GDP, gem-carbo: AUC 4-5 IV q21d. TNBC neoadjuvant (added to AC-T or KEYNOTE-522): AUC 1.5 weekly or AUC 5 q21d with paclitaxel. Lower AUC (3-4) for elderly / frail / heavily pre-treated. |
| Зареєстровано в Україні | True |
| Відшкодовується НСЗУ | True |
| Остання перевірка для України | 2026-04-27 |
Застереження
- Bone marrow suppression — severe thrombocytopenia and neutropenia, dose-limiting
- Anaphylactic / anaphylactoid reactions (risk increases ≥cycle 6 with re-exposure; epinephrine on hand)
Нотатки
Calvert AUC dose calculation requires GFR (Cockcroft-Gault, CKD-EPI, or measured); engine uses creatinine_clearance_ml_min finding for AUC computation. CAP at 125 mL/min per FDA 2010 to prevent overdose. Hypersensitivity prevention: gradual desensitization protocols available for re-exposure beyond cycle 6. Less hydration required than cisplatin (no mandatory pre/post hydration regimen). Platelet nadir day 14-21 — schedule q21d to allow recovery. Monitor CBC weekly for first 4 cycles.
Де використовується
Regimens
REG-AMIVANTAMAB-CHEMO- Amivantamab + Carboplatin + Pemetrexed (NSCLC EGFR-mut post-osimertinib, MARIPOSA-2)REG-CARBO-GEM-BEV-OVARIAN- Carboplatin + Gemcitabine + Bevacizumab (platinum-sensitive recurrent ovarian, OCEANS reg...REG-CARBO-PACLI-ANAL-MET- Carboplatin + paclitaxel (anal carcinoma, metastatic)REG-CARBO-PACLI-CONCURRENT-RT-ESOPH- Weekly carboplatin + paclitaxel concurrent with definitive RT (esophageal)REG-CARBO-PACLI-OVARIAN- Carboplatin + Paclitaxel (ovarian 3-weekly)REG-CARBO-PEM-MOD-ELDERLY- Carboplatin + Pemetrexed (attenuated, NSCLC non-squamous elderly ≥75y)REG-CARBO-PLD-BEV-OVARIAN- Carboplatin + PLD + Bevacizumab (platinum-sensitive recurrent ovarian)REG-CARBOPLATIN-PACLITAXEL-GCT- Carboplatin + Paclitaxel (adult granulosa cell tumor, advanced/recurrent)REG-CARBOPLATIN-PACLITAXEL-WEEKLY- Weekly carboplatin + paclitaxel (CROSS-style chemo backbone)REG-CE-SCLC- Carboplatin + etoposide (SCLC, 1L)REG-DOSTARLIMAB-CARBO-PACLI-ENDOM- Dostarlimab + carbo + paclitaxel (endometrial advanced 1L dMMR)REG-EP-ATEZO-SCLC- Etoposide-platinum + atezolizumab (extensive SCLC, 1L)REG-EP-DURVA-SCLC- Etoposide-platinum + durvalumab (extensive SCLC, 1L)REG-EXTREME-HNSCC- EXTREME (cetuximab + cisplatin/carboplatin + 5-FU; HNSCC R/M, 1L)REG-GEM-CARBO-UROTHELIAL- Gemcitabine + carboplatin (urothelial carcinoma, cisplatin-ineligible)REG-ICE- ICE (Ifosfamide + Carboplatin + Etoposide), 3 cyclesREG-NIVO-IPI-CHEMO-NSCLC-1L- Nivolumab + Ipilimumab + 2-Cycle Platinum-Doublet Chemotherapy (CheckMate-9LA)REG-OSI-PEM-PLATINUM-NSCLC- Osimertinib + pemetrexed + carboplatin/cisplatin (FLAURA-2 regimen, EGFR-mut NSCLC, 1L)REG-PACLITAXEL-CARBOPLATIN-ATC- Paclitaxel + carboplatin (ATC, palliative 1L)REG-PACLITAXEL-CARBOPLATIN-SALIVARY- Paclitaxel + carboplatin (salivary gland carcinoma, palliative)REG-PEMBRO-CARBO-PACLI-ENDOM- Pembrolizumab + carbo + paclitaxel (endometrial advanced 1L)REG-PEMBRO-CHEMO-HNSCC-1L- Pembrolizumab + 5-FU + platinum (HNSCC R/M, 1L; PD-L1 CPS ≥1)REG-PEMBRO-CHEMO-NSCLC-NONSQ- Pembrolizumab + carboplatin + pemetrexed (NSCLC non-squamous, 1L)REG-PEMBRO-CHEMO-TNBC-MET- Pembrolizumab + chemotherapy (TNBC, metastatic PD-L1+)REG-PEMBRO-CHEMO-TNBC-NEOADJUVANT- Pembrolizumab + chemo (TNBC neoadjuvant)REG-PEMBRO-PACLI-CARBO-BEV-CERVICAL- Pembrolizumab + paclitaxel + carboplatin ± bevacizumab (cervical cancer, 1L)REG-PEMBROLIZUMAB-CERVICAL-1L- Pembrolizumab + carboplatin + paclitaxel ± bevacizumab (persistent/recurrent/metastatic c...REG-R-ICE-PMBCL- R-ICE salvage with autoSCT consolidation (relapsed/refractory PMBCL)REG-RETIFANLIMAB-CARBO-PACLI-ANAL-1L- Retifanlimab + carboplatin + paclitaxel (advanced anal SCC 1L, POD1UM-303)REG-RICE-BURKITT- R-ICE (Rituximab + Ifosfamide + Carboplatin + Etoposide) × 2-3 cycles → ASCT in CR2 (r/r...REG-TCHP-NEOADJUVANT- TCHP — docetaxel + carboplatin + trastuzumab + pertuzumab (HER2+ neoadjuvant)